 |
274 Diseases |  |
1060 Trials |
|
1060 Trials |  |
12189 News |  |
| «12345678910111213...178179» |
- | pirfenidone / Generic mfg.
Trial completion date, Metastases: Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC (clinicaltrials.gov) - Jul 9, 2024
P1, N=48, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Jun 2024 --> Sep 2024
- | Keytruda (pembrolizumab) / Merck (MSD), Fruzaqla (fruquintinib) / Takeda
Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker: Case report: Immunotherapy-based combination therapy achieving complete remission and prolonged survival in nasopharyngeal carcinoma with extensive bone marrow metastasis. (Pubmed Central) - Jul 9, 2024
The patient achieved a sustained response with renormalization of tumor markers, imaging findings, and bone biopsies, resulting in complete remission. This case highlights the successful management of nasopharyngeal carcinoma with extensive bone marrow metastasis through an individualized treatment approach incorporating immunotherapy.
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, Combination therapy, Metastases: High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Jul 9, 2024
P2, N=29, Not yet recruiting, Sponsor: Emory University
- || chiauranib (CS 2164) / Chipscreen
New P2 trial, Metastases: Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jul 9, 2024
P2, N=42, Not yet recruiting, Sponsor: Chipscreen Biosciences, Ltd.
- || Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial: Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer (clinicaltrials.gov) - Jul 9, 2024
P2, N=23, Not yet recruiting, Sponsor: Dustin Deming
- | Yidafan (ivonescimab) / Akesobio, Summit Therap
New P2 trial, Combination therapy: Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer (clinicaltrials.gov) - Jul 8, 2024
P2, N=36, Recruiting, Sponsor: Wuhan Union Hospital, China
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Trial completion date, Trial primary completion date, Combination therapy, Metastases: TORCHLIGHT: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment (clinicaltrials.gov) - Jul 8, 2024
P3, N=531, Active, not recruiting, Sponsor: Shanghai Junshi Bioscience Co., Ltd.
This case highlights the successful management of nasopharyngeal carcinoma with extensive bone marrow metastasis through an individualized treatment approach incorporating immunotherapy. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- | albumin-bound paclitaxel / Generic mfg.
Journal: "Abraxane-Like" Radiosensitizer for In Situ Oral Cancer Therapy. (Pubmed Central) - Jul 8, 2024
Furthermore, in animal models of in situ oral cancer, CaO2-HSA can effectively inhibit tumor growth. With its high efficacy, facile preparation, and heavy-metal free biosafety, the CaO2-HSA-based radiosensitizer holds enormous potential for oral cancer therapy.
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial primary completion date, Metastases: FUNGEMAX: First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI (clinicaltrials.gov) - Jul 8, 2024
P2, N=288, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
With its high efficacy, facile preparation, and heavy-metal free biosafety, the CaO2-HSA-based radiosensitizer holds enormous potential for oral cancer therapy. Trial primary completion date: Jun 2024 --> Sep 2024
- || AMG 193 / Amgen
Enrollment change, Combination therapy, Metastases: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) - Jul 8, 2024
P1, N=188, Recruiting, Sponsor: Amgen
Trial primary completion date: Jun 2024 --> Sep 2024 N=282 --> 188
- | Tyvyt (sintilimab) / Eli Lilly
Enrollment closed: NEOTIDE: Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC (clinicaltrials.gov) - Jul 7, 2024
P2, N=35, Active, not recruiting, Sponsor: Guangdong Provincial People's Hospital
N=282 --> 188 Recruiting --> Active, not recruiting
- || Cyramza (ramucirumab) / Eli Lilly
Trial completion date, Trial primary completion date, Metastases: SOCRATE: Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients (clinicaltrials.gov) - Jul 7, 2024
P2, N=112, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Recruiting --> Active, not recruiting Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | albumin-bound paclitaxel / Generic mfg.
Journal, Metastases: Therapeutic effect of induction therapy including nab-paclitaxel followed by surgical resection for the patients with locally advanced non-small-cell lung cancer. (Pubmed Central) - Jul 6, 2024
The therapeutic effect of induction therapy including nab-PTX was promising. Induction CRT, including nab-PTX, followed by resection, may be a viable alternative treatment option for locally advanced NSCLC.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
P1 data, Journal: A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure. (Pubmed Central) - Jul 5, 2024
Second-line S-IROX treatment was deemed acceptable. The RD was set at level-1 dose (S-1, 80
- | Yidafan (ivonescimab) / Akesobio, Summit Therap
New P2 trial, Metastases: AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients (clinicaltrials.gov) - Jul 5, 2024
P2, N=30, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Avastin (bevacizumab) / Roche
New P2 trial, Combination therapy: Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis (clinicaltrials.gov) - Jul 5, 2024
P2, N=42, Enrolling by invitation, Sponsor: Wuhan Union Hospital, China
- ||||| datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Enrollment closed, Metastases: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) (clinicaltrials.gov) - Jul 4, 2024
P3, N=637, Active, not recruiting, Sponsor: AstraZeneca
The RD was set at level-1 dose (S-1, 80 Recruiting --> Active, not recruiting
- || pegvorhyaluronidase alfa (PEGPH20) / Halozyme
Trial completion date, Trial primary completion date, Metastases: Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jul 4, 2024
P=N/A, N=110, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
- ||| PF-07934040 / Pfizer
Enrollment open, Combination therapy, IO biomarker, Metastases: A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (clinicaltrials.gov) - Jul 4, 2024
P1, N=330, Recruiting, Sponsor: Pfizer
Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025 Not yet recruiting --> Recruiting
- | Journal: A fresh perspective on advances in pancreatic cancer treatment over the past two decades (Pubmed Central) - Jul 3, 2024
In the past two decades, significant advances have been made in the treatment of pancreatic cancer.Numerous first-line treatments, such as gemcitabine combined with erlotinib, gemcitabine combined with albumin-bound paclitaxel, FOLFIRINOX, and NALIRIFOX, have emerged;surgery-centered treatment has gradually become the mains clinical strategy.However, behind these achievements, the new drugs developed with substantial funding have not extended the median survival time of patients with advanced pancreatic cancer to more than one year; the 5-year survival rate for postoperative patients remains below 30%. While harboring hope and being proactive, researchers must also soberly reflect and continually reassess our direction, in anticipation of bringing tangible clinical benefits to pancreatic cancer patients at an early date.
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Journal: Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. (Pubmed Central) - Jul 3, 2024
Intravital imaging revealed improved vascular patency in live NID2-depleted tumors, with enhanced response to gemcitabine/Abraxane. In orthotopic models, NID2 CRISPRi tumors had less liver metastasis and increased survival, highlighting NID2 as a potential PDAC cotarget.
- | albumin-bound paclitaxel / Generic mfg.
New trial, Metastases: Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer (clinicaltrials.gov) - Jul 3, 2024
P=N/A, N=18, Not yet recruiting, Sponsor: Hunan Cancer Hospital
- | erlotinib / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
New P1/2 trial, Metastases: PANGEA: Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel (clinicaltrials.gov) - Jul 3, 2024
P1/2, N=104, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- | Imfinzi (durvalumab) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial primary completion date, Surgery: SOLARA: Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (clinicaltrials.gov) - Jul 3, 2024
P1/2, N=41, Recruiting, Sponsor: Colette Shen
In orthotopic models, NID2 CRISPRi tumors had less liver metastasis and increased survival, highlighting NID2 as a potential PDAC cotarget. Trial primary completion date: May 2024 --> Aug 2024
- | adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
Enrollment open, Combination therapy, Metastases: Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 27, 2024
P1/2, N=20, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Trial primary completion date: May 2024 --> Aug 2024 Not yet recruiting --> Recruiting
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion date: AGICC: Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates (clinicaltrials.gov) - Jun 27, 2024
P2, N=48, Active, not recruiting, Sponsor: Academic Thoracic Oncology Medical Investigators Consortium
Not yet recruiting --> Recruiting Trial completion date: May 2024 --> May 2025
- | New trial, Real-world evidence, Real-world: Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma?ChinECR? (clinicaltrials.gov) - Jun 27, 2024
P=N/A, N=800, Active, not recruiting, Sponsor: Hebei Medical University Fourth Hospital
- | Enrollment closed, Trial completion date, Trial primary completion date: Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer (clinicaltrials.gov) - Jun 27, 2024
P3, N=324, Active, not recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Trial completion date: May 2024 --> May 2025 Recruiting --> Active, not recruiting | Trial completion date: Oct 2026 --> Apr 2026 | Trial primary completion date: Oct 2025 --> Apr 2024
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Retrospective data, Journal, Metastases: Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. (Pubmed Central) - Jun 26, 2024
This study represents the largest real-world population of mPC patients treated with AG as a second or later line of therapy. It supports the feasibility of this regimen following first-line FOLFIRINOX, particularly in patients with specific clinical and laboratory characteristics who derived prolonged benefit from first-line therapy.
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment open, Metastases: SKB264-?-11: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Jun 26, 2024
P3, N=524, Recruiting, Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
It supports the feasibility of this regimen following first-line FOLFIRINOX, particularly in patients with specific clinical and laboratory characteristics who derived prolonged benefit from first-line therapy. Not yet recruiting --> Recruiting
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: NO.202405-11: Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC (clinicaltrials.gov) - Jun 25, 2024
P2, N=178, Not yet recruiting, Sponsor: Tang-Du Hospital
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
New P3 trial: TQB2450-III-13: Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer (clinicaltrials.gov) - Jun 25, 2024
P3, N=420, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | LY3200882 / Eli Lilly
Trial completion date: A Study of LY3200882 in Participants With Solid Tumors (clinicaltrials.gov) - Jun 25, 2024
P1, N=223, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Trial completion date: Aug 2024 --> Aug 2025
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Halaven (eribulin mesylate) / Eisai
Biomarker, Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Biopsy: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy (clinicaltrials.gov) - Jun 25, 2024
P=N/A, N=5, Terminated, Sponsor: University of Wisconsin, Madison
Trial completion date: Aug 2024 --> Aug 2025 N=35 --> 5 | Trial completion date: Aug 2024 --> Feb 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Feb 2024; slow accrual
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Efficacy and Biomarker Analysis of Neoadjuvant Toripalimab Plus Chemotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer (NSCLC) (32AB) - Jun 25, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_11;
P2
Notably, the CAFF score showed no significant reduction at C1 compared to C0 for non-MPR patients ( P = 0.111). Conclusions : We demonstrated the efficacy of neoadjuvant toripalimab combined with chemotherapy and the predictive value of MFR and CAFF score in neoadjuvant chemoimmunotherapy.
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Journal: Integrated 68Ga-FAPI-04 PET/MR in Pancreatic Cancer: Prediction of Tumor Response and Tumor Resectability After Neoadjuvant Therapy. (Pubmed Central) - Jun 24, 2024
This pilot study demonstrates the value of 68Ga-FAPI PET/MR for the prediction of tumor response and resectability after neoadjuvant therapy. It may aid in individualized patient management by guiding the treatment regimens.
- | albumin-bound paclitaxel / Generic mfg.
Journal, Metastases: Dose delay, dose reduction, and early treatment discontinuation in Black and White women receiving chemotherapy for nonmetastatic breast cancer. (Pubmed Central) - Jun 24, 2024
Toxicities are the most common reason for treatment modifications and need close monitoring in high-risk groups for timely intervention. Dose reductions and early treatment discontinuations occurred more for Black patients and need further study.
- |||| Keytruda (pembrolizumab) / Merck (MSD), vibostolimab/pembrolizumab (MK-7684A) / Merck (MSD)
Trial primary completion date, Combination therapy, Metastases: KEYVIBE 007: Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) (clinicaltrials.gov) - Jun 24, 2024
P3, N=700, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Dose reductions and early treatment discontinuations occurred more for Black patients and need further study. Trial primary completion date: Nov 2025 --> Jun 2026
- || volrustomig (MEDI5752) / AstraZeneca
Trial completion date, Trial primary completion date, Metastases: FTIH: A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jun 24, 2024
P1, N=401, Active, not recruiting, Sponsor: MedImmune LLC
Trial primary completion date: Nov 2025 --> Jun 2026 Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Apr 2025 --> Dec 2025
- | Enrollment change, Trial completion date, Trial primary completion date: EUS-RFA PANCARDINAL-1 Trial (clinicaltrials.gov) - Jun 24, 2024
P2, N=60, Recruiting, Sponsor: The University of Texas Health Science Center, Houston
Trial completion date: Apr 2025 --> Dec 2025 | Trial primary completion date: Apr 2025 --> Dec 2025 N=15 --> 60 | Trial completion date: Jan 2028 --> May 2028 | Trial primary completion date: Jul 2024 --> May 2025
- | Kaitanni (cadonilimab) / Akesobio
New P2 trial, Metastases: The Efficacy of Gemcitabine and Nab-palitaxe Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Patients With Locally Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jun 24, 2024
P2, N=30, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: U1111-1301-2790: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (clinicaltrials.gov) - Jun 24, 2024
P3, N=851, Recruiting, Sponsor: Merck Sharp & Dohme LLC
N=15 --> 60 | Trial completion date: Jan 2028 --> May 2028 | Trial primary completion date: Jul 2024 --> May 2025 Not yet recruiting --> Recruiting
- | thalidomide / Generic mfg.
New P2 trial: Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor (clinicaltrials.gov) - Jun 23, 2024
P2, N=20, Completed, Sponsor: Shandong First Medical University
- | cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
New P2 trial, Combination therapy, Metastases: OPTimal: A Prospective, Randomised Controlled, Phase II Clinical Study of Tirilizumab in Combination With Albumin-bound Paclitaxel With Cisplatin for Neoadjuvant and Adjuvant Treatment of Locally Advanced Resectable Oral Squamous Cell Carcinoma (clinicaltrials.gov) - Jun 23, 2024
P2, N=116, Recruiting, Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Retrospective data, Journal: Adjuvant and post-recurrent treatment patterns in patients with resectable gastric cancer in japan: a retrospective database cohort study. (Pubmed Central) - Jun 22, 2024
Not yet recruiting --> Recruiting This study demonstrated temporal shifts in adjuvant treatment patterns that followed the establishment of novel regimens, and confirmed that post-recurrent treatment patterns were consistent with the Japanese Gastric Cancer Association guideline recommendations.
- ||| P3 data, Journal, Metastases: Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. (Pubmed Central) - Jun 22, 2024
This study demonstrated temporal shifts in adjuvant treatment patterns that followed the establishment of novel regimens, and confirmed that post-recurrent treatment patterns were consistent with the Japanese Gastric Cancer Association guideline recommendations. No abstract available
- || AMG 193 / Amgen
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (clinicaltrials.gov) - Jun 21, 2024
P1, N=282, Recruiting, Sponsor: Amgen
No abstract available Trial completion date: May 2028 --> Nov 2027 | Trial primary completion date: May 2026 --> Nov 2025
- | Kaitanni (cadonilimab) / Akesobio
New P2 trial, Monotherapy, Metastases: A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy (clinicaltrials.gov) - Jun 21, 2024
P2, N=48, Recruiting, Sponsor: Xin-Hua Xu
- || albumin-bound paclitaxel / Generic mfg.
PK/PD data, Journal: Pharmacokinetic evaluation of paclitaxel, albumin-binding paclitaxel, and liposomal-encapsulated albumin-binding paclitaxel upon gastric subserosal administration. (Pubmed Central) - Jun 21, 2024
Trial completion date: May 2028 --> Nov 2027 | Trial primary completion date: May 2026 --> Nov 2025 To attenuate systemic side effects, we evaluated the effectiveness of regional chemotherapy using paclitaxel, albumin-paclitaxel, and liposome-encapsulated albumin-paclitaxel via subserosal injection in rat models employing nuclear medicine and molecular imaging technology...The time to reach the maximum concentration in the intestine for L-APNs, paclitaxel, and APNs was 6.67, 5.33, and 4.00
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma, adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab Plus Chemo and Recaticimab Perioperative Treatment for Resectable NSCLC (clinicaltrials.gov) - Jun 21, 2024
P2, N=35, Not yet recruiting, Sponsor: Beijing Chest Hospital, Capital Medical University